In vitro engineering of heart muscle: Artificial myocardial tissue

Kofidis, Theo; Akhyari, Payam; Boublik, Jan; Theodorou, Panagiotis; Martin, Ulrich; Ruhparwar, Arjang; Fischer, Stefan; Eschenhagen, Thomas; Kubis, Hans-Peter; Kraft, Theresia; Leyh, Rainer; Haverich, Axel

doi:10.1067/mtc.2002.121971

Cited by 125 publications

(64 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25 Crude myocyte cultures were mainly contaminated with fibroblasts, and, to a lower extent, with endothelial and smooth muscle cells. Freshly isolated neonatal rat cardiomyocytes and RAT-1 fibroblasts (NIH RAT-1) were transduced in suspension in a rotation incubator at a MOI of 7 in DMEM with 10% fetal calf serum (Invitrogen, Karlsruhe, Germany), 2 mmol/l L-glutamine (PAA, Linz, Austria), penicillin (PAA, Linz, Austria, 100 U/ml) and streptomycin (PAA, Linz, Austria, 100 mg/ml).…”

Section: Lentiviral Transduction Of Cardiomyocytes and Rat-1 Fibroblamentioning

confidence: 99%

Shuttle of lentiviral vectors via transplanted cells in vivo

et al. 2004

View full text Add to dashboard Cite

Section: Lentiviral Transduction Of Cardiomyocytes and Rat-1 Fibroblamentioning

confidence: 99%

Shuttle of lentiviral vectors via transplanted cells in vivo

et al. 2004

View full text Add to dashboard Cite

“…Coculturing neonatal cardiomyocytes, fibroblasts and collagen within bioreactors produced constructs that may promise for the repair of larger scar areas of the myocardium (Van Luyn et al 2002). Seeded neonatal rat cardiomyocytes in a collagen matrix demonstrated contractility both spontaneously and in response to electrical and chemical stimulation (Kofidis et al 2002). Further work on the tissue engineering of cardiac muscle suggested that such constructs had superior wall thickness and uniformity of tissue architecture when perfused (Carrier et al 2002a).…”

Section: Cardiovascular Systemmentioning

confidence: 99%

Challenges in tissue engineering

Ikada

2006

J. R. Soc. Interface.

771

511

View full text Add to dashboard Cite

Almost 30 years have passed since a term 'tissue engineering' was created to represent a new concept that focuses on regeneration of neotissues from cells with the support of biomaterials and growth factors. This interdisciplinary engineering has attracted much attention as a new therapeutic means that may overcome the drawbacks involved in the current artificial organs and organ transplantation that have been also aiming at replacing lost or severely damaged tissues or organs. However, the tissues regenerated by this tissue engineering and widely applied to patients are still very limited, including skin, bone, cartilage, capillary and periodontal tissues. What are the reasons for such slow advances in clinical applications of tissue engineering? This article gives the brief overview on the current tissue engineering, covering the fundamentals and applications. The fundamentals of tissue engineering involve the cell sources, scaffolds for cell expansion and differentiation and carriers for growth factors. Animal and human trials are the major part of the applications. Based on these results, some critical problems to be resolved for the advances of tissue engineering are addressed from the engineering point of view, emphasizing the close collaboration between medical doctors and biomaterials scientists.

show abstract

“…Tissue engineering using biological and synthetic matrix is now associated with cell therapy, the goal is to develop a bioartificial myocardium [22][23][24][25][26][27]. The MAGNUM Clinical Trial (Myocardial Assistance by Grafting a New Upgraded bioartificial Myocardium) is under development by our group [28].…”

Section: Cellular Cardiomyoplastymentioning

confidence: 99%

Development of Bioartificial Myocardium Using Stem Cells and Nanobiotechnology Templates

Chachques

2013

Current Therapies in Regenerative Medicine

View full text Add to dashboard Cite

Cell-based regenerative therapy is undergoing experimental and clinical trials in cardiology, in order to limit the consequences of decreased contractile function and compliance of damaged ventricles following myocardial infarction. Over 1000 patients have been treated worldwide with cell-based procedures for myocardial regeneration. Cellular cardiomyoplasty seems to reduce the size and fibrosis of infarct scars, limit adverse postischemic remodelling, and improve diastolic function. The development of a bioartificial myocardium is a new challenge; in this approach, tissue-engineered procedures are associated with cell therapy. Organ decellularization for bioscaffolds fabrication is a new investigated concept. Nanomaterials are emerging as the main candidates to ensure the achievement of a proper instructive cellular niche with good drug release/administration properties. Investigating the electrophysiological properties of bioartificial myocardium is the challenging objective of future research, associating a multielectrode network to provide electrical stimulation could improve the coupling of grafted cells and scaffolds with host cardiomyocytes. In summary, until now stem cell transplantation has not achieved clear hemodynamic benefits for myocardial diseases. Supported by relevant scientific background, the development of myocardial tissue engineering may constitute a new avenue and hope for the treatment of myocardial diseases.

show abstract

In vitro engineering of heart muscle: Artificial myocardial tissue

Cited by 125 publications

References 8 publications

Shuttle of lentiviral vectors via transplanted cells in vivo

Shuttle of lentiviral vectors via transplanted cells in vivo

Challenges in tissue engineering

Development of Bioartificial Myocardium Using Stem Cells and Nanobiotechnology Templates

Contact Info

Product

Resources

About